Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $16,236 - $22,075
811 Added 0.64%
127,435 $2.85 Million
Q1 2023

May 12, 2023

SELL
$33.3 - $44.82 $664,801 - $894,786
-19,964 Reduced 13.62%
126,624 $4.72 Million
Q4 2022

Feb 08, 2023

SELL
$33.21 - $62.69 $345,682 - $652,540
-10,409 Reduced 6.63%
146,588 $5.11 Million
Q3 2022

Nov 09, 2022

BUY
$53.92 - $71.7 $2 Million - $2.66 Million
37,062 Added 30.9%
156,997 $8.79 Million
Q2 2022

Aug 10, 2022

SELL
$38.49 - $76.21 $1.11 Million - $2.19 Million
-28,766 Reduced 19.34%
119,935 $6.21 Million
Q1 2022

May 04, 2022

SELL
$58.27 - $118.99 $284,648 - $581,266
-4,885 Reduced 3.18%
148,701 $10.8 Million
Q4 2021

Feb 10, 2022

BUY
$100.76 - $138.36 $70,733 - $97,128
702 Added 0.46%
153,586 $18.2 Million
Q3 2021

Nov 10, 2021

BUY
$132.37 - $176.78 $1.21 Million - $1.61 Million
9,125 Added 6.35%
152,884 $20.5 Million
Q2 2021

Aug 13, 2021

BUY
$60.88 - $161.91 $161,758 - $430,194
2,657 Added 1.88%
143,759 $23.3 Million
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $1.25 Million - $2.25 Million
26,868 Added 23.52%
141,102 $11.3 Million
Q4 2020

Feb 02, 2021

BUY
$18.83 - $63.53 $16,043 - $54,127
852 Added 0.75%
114,234 $6.21 Million
Q3 2020

Nov 05, 2020

BUY
$17.47 - $24.93 $431,194 - $615,322
24,682 Added 27.83%
113,382 $2.25 Million
Q2 2020

Aug 12, 2020

BUY
$11.14 - $22.87 $110,286 - $226,413
9,900 Added 12.56%
88,700 $1.86 Million
Q1 2020

May 12, 2020

BUY
$9.44 - $15.58 $118,000 - $194,750
12,500 Added 18.85%
78,800 $964,000
Q4 2019

Jan 27, 2020

BUY
$10.43 - $17.67 $572,607 - $970,083
54,900 Added 481.58%
66,300 $973,000
Q3 2019

Oct 31, 2019

BUY
$13.07 - $18.51 $148,998 - $211,014
11,400 New
11,400 $152,000
Q3 2018

Nov 13, 2018

SELL
$25.78 - $32.6 $274,247 - $346,798
-10,638 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$20.02 - $30.79 $212,972 - $327,544
10,638 New
10,638 $291,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.